NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Stock Has Average Price Target of $170.00

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $170.00.

NRSN has been the subject of several research reports. Weiss Ratings lowered NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th. HC Wainwright started coverage on NeuroSense Therapeutics in a research note on Thursday, September 3rd. They issued a “buy” rating on the stock.

NeuroSense Therapeutics Price Performance

Shares of NRSN opened at $6.95 on Friday. NeuroSense Therapeutics has a one year low of $5.00 and a one year high of $26.64. The company has a 50-day simple moving average of $8.93 and a two-hundred day simple moving average of $13.15. The firm has a market capitalization of $13.21 million, a PE ratio of -0.64 and a beta of 1.60.

Institutional Trading of NeuroSense Therapeutics

An institutional investor recently bought a new position in NeuroSense Therapeutics stock. Yorkville Advisors Global LP bought a new position in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 100,000 shares of the company’s stock, valued at approximately $77,000. NeuroSense Therapeutics accounts for about 0.0% of Yorkville Advisors Global LP’s holdings, making the stock its 24th biggest holding. Yorkville Advisors Global LP owned approximately 0.73% of NeuroSense Therapeutics as of its most recent SEC filing. 1.04% of the stock is currently owned by institutional investors and hedge funds.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is headquartered in Israel and conducts research aimed at addressing biological mechanisms associated with diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurological disorders.

NeuroSense’s leading investigational product is PrimeC, an oral, fixed-dose combination of ciprofloxacin and celecoxib. The therapy is designed to target multiple disease-related pathways, including neuroinflammation and the regulation of RNA processing, and has been evaluated in clinical studies involving patients with ALS.